Tumor progression is accelerated via heterogeneous mechanisms including dysfunctional/deleted VHL gene in renal cell carcinoma and hemangioblastoma [8], inactivated IDH1 gene in glioblastoma [9], mutations in mitochondrial succinic dehydrogenases in paraganglioma, and others [10]. This evidence concerns the gene IDH1 and glioblastoma.